World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
84
Citations
32773
World Ranking
3261
National Ranking
1651

Peter D. Senter publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Peter D. Senter sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 257 publications — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Peter D. Senter D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Peter D. Senter sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 84 D-Index — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Peter D. Senter is affiliated with Seattle Genetics in the United States. Their research work spans various domains within medicine and biochemistry, genetics, and molecular biology, focusing primarily on oncology and molecular biology subfields. They have authored multiple publications related to cancer research, drug development, and immunology topics.

The scientist's recent papers include:

  • Antibody-drug conjugates come of age in oncology, 2023, Nature Reviews Drug Discovery
  • Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers, 2020, Molecular Cancer Therapeutics
  • Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux-positive Tumor Models, 2020, Molecular Cancer Therapeutics
  • Improving Antibody-Tubulysin Conjugates through Linker Chemistry and Site-Specific Conjugation, 2020, ChemMedChem
  • Structure-activity relationships of tubulysin analogues, 2020, Bioorganic & Medicinal Chemistry Letters

Frequent coauthors collaborating with Peter D. Senter include:

  • Jessica K. Simmons
  • Scott C. Jeffrey
  • Shyra J. Gardai
  • Kim K. Emmerton
  • Robert P. Lyon

Peter D. Senter's work has appeared predominantly in the following publication venues:

  • Cancer Research (6 publications)
  • Molecular Cancer Therapeutics (5 publications)
  • ChemMedChem (2 publications)
  • Nature Reviews Drug Discovery (1 publication)
  • Science Advances (1 publication)

The primary fields of study for this scientist are Medicine and Biochemistry, Genetics and Molecular Biology, with a notable focus on the subfields of Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Immunology, and Infectious Diseases.

Main research topics covered by Peter D. Senter include:

  • Monoclonal and Polyclonal Antibodies Research
  • HER2/EGFR in Cancer Research
  • CAR-T cell therapy research
  • Glycosylation and Glycoproteins Research
  • Cancer therapeutics and mechanisms
  • Bioactive Compounds and Antitumor Agents
  • Cancer Treatment and Pharmacology

Best Publications

  • Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

    Svetlana O Doronina;Brian E Toki;Michael Y Torgov;Brian A Mendelsohn

  • Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate

    Kevin J. Hamblett;Peter D. Senter;Dana F. Chace;Michael M. C. Sun

  • cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

    Joseph A Francisco;Charles G Cerveny;Damon L Meyer;Bruce J Mixan

  • Arming antibodies: prospects and challenges for immunoconjugates

    Anna M Wu;Peter D Senter

  • conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga

    Allen J Ebens;Brian E Toki;Mark X Sliwkowski;Paul Polakis

  • The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

    Peter D Senter;Eric L Sievers

  • Antibody-Drug Conjugates in Cancer Therapy

    Eric L Sievers;Peter D Senter

  • Antibody–drug conjugates: targeted drug delivery for cancer

    Stephen C Alley;Nicole M Okeley;Peter D Senter

  • Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity

    Svetlana O. Doronina;Brian A. Mendelsohn;Tim D. Bovee;Charles G. Cerveny

  • Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells

    Peter D. Senter;Mark G. Saulnier;Joseph P. Brown;David E. Kerr

  • Contribution of linker stability to the activities of anticancer immunoconjugates.

    Stephen C. Alley;Dennis R. Benjamin;Scott C. Jeffrey;Nicole M. Okeley

  • Lægemiddelkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektionssygdom

    Senter Peter D;Doronina Svetlana;Toki Brian E

  • Potent antibody drug conjugates for cancer therapy.

    Peter D Senter

  • Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index.

    Robert P Lyon;Tim D Bovee;Svetlana O Doronina;Patrick J Burke

  • SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

    May S. Kung Sutherland;Roland B. Walter;Scott C. Jeffrey;Patrick J. Burke

  • Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides

    Michael M. C. Sun;Kevin S. Beam;Charles G. Cerveny;Kevin J. Hamblett

  • Efficient Cancer Therapy with a Nanobody-Based Conjugate

    Virna Cortez-Retamozo;Natalija Backmann;Peter D. Senter;Ullrich Wernery

  • Antibody-drug conjugates for cancer therapy.

    Paul J. Carter;Peter D. Senter

  • Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.

    Nicole M Okeley;Jamie B Miyamoto;Xinqun Zhang;Russell J Sanderson

  • In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate

    Russell J. Sanderson;Michelle A. Hering;Stephanie F. James;Michael M.C. Sun

Frequent Co-Authors

Peter S. Linsley
Peter S. Linsley Benaroya Research Institute
Paul Polakis
Paul Polakis Genentech
Karl Erik Hellström
Karl Erik Hellström University of Washington
Ingegerd Hellström
Ingegerd Hellström University of Washington
John M. Lambert
John M. Lambert ImmunoGen (United States)
Paul J. Maddon
Paul J. Maddon Columbia University
Irwin D. Bernstein
Irwin D. Bernstein Fred Hutchinson Cancer Research Center
Robert M. Coates
Robert M. Coates University of Illinois at Urbana-Champaign
Herren Wu
Herren Wu AstraZeneca (United Kingdom)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Expanding your expertise in Biology and Biochemistry can open doors to a wide range of healthcare and science-related careers. Many students pursue advanced education through flexible online programs tailored to fit diverse professional goals and schedules.

For those interested in advanced nursing leadership, several online dnp programs without clinicals are available, eliminating the need for on-site practice while still delivering rigorous educational content. Alternatively, management-focused programs such as a doctorate in healthcare management prepare graduates for high-level administrative roles across hospitals and clinics.

If your interests lean toward pharmacological sciences, an online pharmacy school can help you achieve the qualifications needed to become a licensed pharmacist or researcher. Additionally, those looking to combine a passion for health and human performance may consider earning an exercise science degree online accredited by recognized bodies, which opens up careers in clinical settings, wellness coaching, and sports medicine.

Best Scientists Citing Peter D. Senter

Trending Scientists

Recently Published Articles